| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
GENEVA—SpinX Technologies,  a provider of biological assay technology, recently secured Euro 10 million ($12.5 million) in Series B financing led by Bio Fund Management. Also involved in the financing—which will support the further development and initial commercialization of SpinX's programmable microfluidics platform to perform biological assays—were Index Ventures, Auriga Partners, DFJ ePlanet Ventures and the CERN Pension Fund.
 
"This financing will allow us to set up the outsourced manufacturing for the consumable part of our technology, the microfluidic cards, which are produced using micro-injection molding," explains Dr. Bart Van de Vyver, SpinX's co-founder and head of corporate development. "It will also aid us in commercially launching the SpinX technology for its first application, which is the profiling of drug candidates."
 
In addition to marketing the technology for drug discovery, potential applications can also be found—and will likely be explored—in areas such as genetic testing and clinical diagnostics.
 
The SpinX technology integrates assay preparation and readouts in a single benchtop device that reportedly increases flexibility in designing experiments and substantially reduces the manual work involved in setting up and performing biological assays.
 
"Our technology is surprisingly simple," maintains Piero Zucchelli, co-founder of SpinX and head of research and product development. "It is entirely based on off-the-shelf components and technologies. The main challenge in developing the platform was the integration of very diverse components—something we are used to dealing with from our days at [European particle physics laboratory] CERN. At SpinX, the biology and chemistry adds another dimension, but we've overcome this challenge thanks to our highly diverse and committed team."

About the Author

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue